Femasys Inc. (NASDAQ:FEMY) Short Interest Update

Femasys Inc. (NASDAQ:FEMY) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 684,700 shares, an increase of 24.3% from the August 31st total of 550,800 shares. Based on an average daily trading volume, of 141,200 shares, the short-interest ratio is currently 4.8 days. Currently, 3.3% of the company’s shares are sold short.

Femasys Stock Performance

Shares of Femasys stock opened at $1.12 on Monday. Femasys has a one year low of $0.73 and a one year high of $4.75. The company has a market capitalization of $24.89 million, a PE ratio of -1.33 and a beta of -2.81. The company has a debt-to-equity ratio of 0.43, a quick ratio of 5.93 and a current ratio of 6.47. The company has a 50-day simple moving average of $1.09 and a two-hundred day simple moving average of $1.23.

Femasys (NASDAQ:FEMY) last posted its earnings results on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). The firm had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.50 million. Femasys had a negative net margin of 1,757.16% and a negative return on equity of 119.97%. Research analysts expect that Femasys will post -0.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on FEMY. Chardan Capital decreased their price target on shares of Femasys from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Femasys in a report on Thursday, September 12th.

Institutional Trading of Femasys

A hedge fund recently raised its stake in Femasys stock. Clear Creek Financial Management LLC boosted its holdings in shares of Femasys Inc. (NASDAQ:FEMY) by 30.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 309,274 shares of the company’s stock after buying an additional 72,505 shares during the period. Clear Creek Financial Management LLC owned approximately 1.40% of Femasys worth $479,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.